Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3985454 | 0.98 | ALDH1A1 (0.48) | BBOX1TSHRALDH1A1LMNAAPEX1 | |
| Water SCHEMBL10920607 | 0.98 | BBOX1 (0.46) | BBOX1TSHRALDH1A1LMNAAPEX1 | |
| Betaine SCHEMBL1356056 | 0.94 | TSHR (0.58) | BBOX1TSHRALDH1A1LMNAAPEX1 | |
| Bicarbonate SCHEMBL2704201 | 0.82 | BBOX1 (0.52) | BBOX1TSHRALDH1A1LMNAAPEX1 | |
| Succinic Acid SCHEMBL28710004 | 0.81 | BBOX1 (0.52) | BBOX1TSHRALDH1A1LMNAKMT2A | |
| SCHEMBL6277757 | 0.79 | BBOX1 (0.60) | BBOX1ALDH1A1KMT2AATMACHE | |
| Hydrochloric Acid SCHEMBL3985779 | 0.79 | ALDH1A1 (0.48) | BBOX1TSHRALDH1A1LMNAAPEX1 | |
| Bromide SCHEMBL9495868 | 0.79 | BBOX1 (0.46) | BBOX1ALDH1A1LMNAKMT2AATM | |
| Bicarbonate SCHEMBL2704202 | 0.78 | BBOX1 (0.59) | BBOX1TSHRALDH1A1LMNAKMT2A | |
| Acrylic Acid SCHEMBL27587559 | 0.78 | LMNA (0.50) | BBOX1TSHRALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109847800-A | A kind of poly- carboxyl type heteropoly acid poly ion liquid and its preparation method and application | 闽江学院 | 2019-06-07 | — | — | CN | claimed |
| US-7591949-B2 | Method for the improvement of transport across adaptable semi-permeable barriers | IDEA AG (DE) | 2009-09-22 | — | — | US | claimed |
| US-20080311184-A1 | METHOD FOR DEVELOPING, TESTING, AND USING ASSOCIATES OF MACROMOLECULES AND COMPLEX AGGREGATES FOR IMPROVED PAYLOAD AND CONTROLLABLE DE/ASSOCIATION RATES | IDEA AG (DE) | 2008-12-18 | — | — | US | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | IDEA AG (DE) | 2007-08-09 | — | — | US | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| US-20050123897-A1 | Method for the improvement of transport across adaptable semi-permeable barriers | IDEA AG | 2005-06-09 | — | — | US | claimed |
| EP-1140021-B1 | IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO | IDEA AG (DE) | 2004-08-04 | — | — | EP | claimed |
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2004-06-03 | — | — | US | claimed |
| US-20030099694-A1 | Method for the improvement of transport across adaptable semi-permeable barriers | IDEA AG (DE) | 2003-05-29 | — | — | US | claimed |
| US-5900386-A | GROUP IB OR 8 METALS ON SUPPORT | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1999-05-04 | — | — | US | claimed |
| US-5681808-A | Detergent compositions | DOW CORNING TORAY SILICONE CO., LTD. (JP) | 1997-10-28 | — | — | US | claimed |
| EP-0745648-A2 | Stable dispersible silicone compositions | DOW CORNING CORPORATION (US) | 1996-12-04 | — | — | EP | claimed |
| EP-0004137-B1 | IMMUNOGENIC CELL ENVELOPE PREPARATIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1981-11-11 | — | — | EP | claimed |
| US-4248862-A | Immunogenic cell envelope preparations | THE SECRETARY OF STATE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1981-02-03 | — | — | US | claimed |
| EP-0004137-A1 | Immunogenic cell envelope preparations | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1979-09-19 | — | — | EP | claimed |
| US-20240099976-A1 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2024-03-28 | — | — | US | disclosed |
| EP-0004137-A1 | Immunogenic cell envelope preparations | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1979-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040105881-A1 | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | CUTA, ABCG2, PIGS | BBOX1 4663/4885TSHR 3410/4885ALDH1A1 2042/4885 |
| US-20070184114-A1 | Formulation for topical non-invasive application in vivo | GPX4, LPO, MMP8 | BBOX1 855/4885TSHR 4612/4885ALDH1A1 2763/4885 |
| US-20030099694-A1 | Method for the improvement of transport across adaptable semi-permeable barriers | ABCG2, NPC1L1, KIT | BBOX1 4668/4885TSHR 3118/4885ALDH1A1 2445/4885 |
| US-20050123897-A1 | Method for the improvement of transport across adaptable semi-permeable barriers | NPC1L1, ABCG2, SLC7A1 | BBOX1 4790/4885TSHR 2897/4885ALDH1A1 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.